Pharmaceuticals, Biotechnology and Life Sciences
AstraZeneca and MSD’s Lynparza (olaparib) has been approved in the European Union (EU) for the 1st-line maintenance treatment with bevacizumab of patients with homologous recombination deficient (HRD)-positive advanced ovarian cancer.
Gyroscope doses first patient in Phase II EXPLORE trial evaluating GT005 in people with geographic atrophy secondary to dry AMD with a mutation in the Complement Factor I gene.
VarmX, a biotech company focusing on the development of innovative approaches for the reversal of anticoagulation, today announces the completion of a €32 million Series B financing round.
Vetter and Rentschler Biopharma have announced joining forces to boost their services and along the biopharmaceutical value chain.
Abivax has treated the first patient in its Phase 2b/3 study of ABX464 in COVID-19 patients at the University Hospital Center in Nice, France (CHU Nice) in a randomized, double-blind, placebo-controlled study, to see the the effects of early treatment in 1034 Covid-19 older or high-risk patients.
EUSA Pharma, a global biopharmaceutical company focused on oncology and rare disease, received the approval from the U.S. Food & Drug Administration (FDA) for a randomized, double-blind, placebo-controlled Phase 3 clinical trial to test intravenous siltuximab plus standard of care in hospitalized patients with COVID-19 associated Acute Respiratory Distress Syndrome (ARDS).
BALLERUP, Denmark–(BUSINESS WIRE)–LEO Pharma, a global leader in medical dermatology, today announced that Dr. Monica Shaw, M.D., and Nathalie Joannes…
As Vertex expands deal with NHS England to include Kaftrio in combination with Kalydeco, the cysitc fibrosis patients in England will be among the first in Europe to benefit from access to Kaftrio, if the medicine is approved by the European Commission.
Italy-based Stevanato Group, a leading producer of pharmaceutical glass containers and integrated provider of drug delivery systems, continued its growth in 2019, recording a positive trend on key financial indicators, with consolidated revenues of €570.3 million, an increase of +10.9% compared to 2018.
Mereo BioPharma has named several new positions this week, thus reaffirming it’s management team with those appointments.